References
1. Viegas C, Araújo N, Marreiros C, Simes D: The interplay between
mineral metabolism, vascular calcification and inflammation in chronic
kidney disease (CKD): Challenging old concepts with new facts.Aging (Albany NY) 11: 4274-4299, 2019.
2. Lee SJ, Lee I-K, Jeon J-H: Vascular calcification—new insights into
its mechanism. Int J Mol Sci 21: 2685, 2020.
3. Vahed SZ, Mostafavi S, Khatibi SMH, Shoja MM, Ardalan M: Vascular
calcification: An important understanding in nephrology. Vasc
Health Risk Manag 16: 167-180, 2020.
4. Affret A, Wagner S, El Fatouhi D, Dow C, Correia E, Niravong M, et
al.: Validity and reproducibility of a short food frequency
questionnaire among patients with chronic kidney disease. BMC
Nephrol 18: 297, 2017.
5. Ketteler M, Block GA, Evenepoel P, Fukagawa M, Herzog CA, McCann L,
et al.: Diagnosis, evaluation, prevention, and treatment of chronic
kidney disease–mineral and bone disorder: Synopsis of the kidney
disease: Improving global outcomes 2017 clinical practice guideline
update. Amm Intern Med 168: 422-430, 2018.
6. Isakova T, Nickolas TL, Denburg M, Yarlagadda S, Weiner DE, Gutiérrez
OM, et al.: KDOQI us commentary on the 2017 KDIGO clinical practice
guideline update for the diagnosis, evaluation, prevention, and
treatment of chronic kidney disease–mineral and bone disorder
(CKD-MBD). Am J Kidney Dis 70: 737-751, 2017.
7. Locatelli F, Del Vecchio L, Violo L, Pontoriero G: Phosphate binders
for the treatment of hyperphosphatemia in chronic kidney disease
patients on dialysis: A comparison of safety profiles. Expert Opin
Drug Saf 13: 551-561, 2014.
8. Hutchison AJ: Oral phosphate binders. Kidney Int 75: 906-914,
2009.
9. Ruospo M, Palmer SC, Natale P, Craig JC, Vecchio M, Elder GJ, et al.:
Phosphate binders for preventing and treating chronic kidney
disease-mineral and bone disorder (CKD-MBD). Cochrane Database
Syst Rev 8: CD006023, 2018.
10. Chen NX, Duan D, O’Neill KD, Wolisi GO, Koczman JJ, Laclair R, et
al.: The mechanisms of uremic serum-induced expression of bone matrix
proteins in bovine vascular smooth muscle cells. Kidney Int 70:
1046-1053, 2006.
11. Muteliefu G, Enomoto A, Jiang P, Takahashi M, Niwa T: Indoxyl
sulphate induces oxidative stress and the expression of
osteoblast-specific proteins in vascular smooth muscle cells.Nephrol Dial Transplant 24: 2051-2058, 2009.
12. Zheng CM, Lu KC, Wu CC, Hsu YH, Lin YF: Association of serum
phosphate and related factors in esrd-related vascular calcification.Int J Nephrol 2011: 939613, 2011.
13. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al.:
Effects of sevelamer on HbA1c, inflammation, and advanced glycation end
products in diabetic kidney disease. Clin J Am Soc Nephrol 7:
934-942, 2012.
14. Chertow GM, Burke SK, Raggi P, Treat to Goal Working G: Sevelamer
attenuates the progression of coronary and aortic calcification in
hemodialysis patients. Kidney Int 62: 245-252, 2002.
15. Qunibi WY, Hootkins RE, McDowell LL, Meyer MS, Simon M, Garza RO, et
al.: Treatment of hyperphosphatemia in hemodialysis patients: The
Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 65:
1914-1926, 2004.
16. Evenepoel P, Selgas R, Caputo F, Foggensteiner L, Heaf JG, Ortiz A,
et al.: Efficacy and safety of sevelamer hydrochloride and calcium
acetate in patients on peritoneal dialysis. Nephrol Dial
Transplant 24: 278-285, 2009.
17. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB: Reappraisal of the
pathogenesis and consequences of hyperuricemia in hypertension,
cardiovascular disease, and renal disease. Am J Kidney Dis 33:
225-234, 1999.
18. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A,
et al.: Fibroblast growth factor 23 (FGF23) predicts progression of
chronic kidney disease: The mild to moderate kidney disease (MMKD)
study. J Am Soc Nephrol 18: 2600-2608, 2007.
19. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone
G, et al.: Fibroblast growth factor-23 and left ventricular hypertrophy
in chronic kidney disease. Circulation 119: 2545, 2009.
20. Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, et
al.: Fibroblast growth factor-23 mitigates hyperphosphatemia but
accentuates calcitriol deficiency in chronic kidney disease. J Am
Soc Nephrol 16: 2205-2215, 2005.
21. Giachelli CM, Jono S, Shioi A, Nishizawa Y, Mori K, Morii H:
Vascular calcification and inorganic phosphate. Am J Kidney Dis38: S34-37, 2001.
22. Russo D, Palmiero G, De Blasio AP, Balletta MM, Andreucci VE:
Coronary artery calcification in patients with CRF not undergoing
dialysis. Am J Kidey Dis 44: 1024-1030, 2004.
23. Nagano N, Miyata S, Abe M, Kobayashi N, Wakita S, Yamashita T, et
al.: Effect of manipulating serum phosphorus with phosphate binder on
circulating pth and FGF23 in renal failure rats. Kidney Int 69:
531-537, 2006.
24. Oliveira RB, Cancela AL, Graciolli FG, Dos Reis LM, Draibe SA,
Cuppari L, et al.: Early control of pth and FGF23 in normophosphatemic
CKD patients: A new target in CKD-MBD therapy? Clin J Am Soc
Nephrol 5: 286-291, 2010.
25. Sigrist M, Bungay P, Taal MW, McIntyre CW: Vascular calcification
and cardiovascular function in chronic kidney disease. Nephrol
Dial Transplant 21: 707-714, 2006.
26. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B, et al.:
High levels of serum fibroblast growth factor (FGF)-23 are associated
with increased mortality in long haemodialysis patients. Nephrol
Dial Transplant 24: 2792-2796, 2009.
27. Llauradó G, Megia A, Cano A, Giménez-Palop O, Simón I,
González-Sastre M, et al.: FGF-23/vitamin D axis in type 1 diabetes: The
potential role of mineral metabolism in arterial stiffness. PloS
One 10: e0140222, 2015.
28. Moe SM, Reslerova M, Ketteler M, O’Neill K, Duan D, Koczman J, et
al.: Role of calcification inhibitors in the pathogenesis of vascular
calcification in chronic kidney disease (CKD). Kidney Int 67:
2295-2304, 2005.
29. Brown RB, Razzaque MS: Dysregulation of phosphate metabolism and
conditions associated with phosphate toxicity. Bonekey Rep 4:
705, 2015.
30. Tousoulis D, Siasos G, Maniatis K, Oikonomou E, Vlasis K,
Papavassiliou AG, et al.: Novel biomarkers assessing the calcium
deposition in coronary artery disease. Curr Med Chem 19: 901-920,
2012.
31. D’Marco L, Bellasi A, Raggi P: Cardiovascular biomarkers in chronic
kidney disease: State of current research and clinical applicability.Dis Markers 2015: 586569, 2015.
32. Wang C, Liu X, Zhou Y, Li S, Chen Y, Wang Y, et al.: New conclusions
regarding comparison of sevelamer and calcium-based phosphate binders in
coronary-artery calcification for dialysis patients: A meta-analysis of
randomized controlled trials. PloS One 10: e0133938, 2015.
33. Arici M, Kahraman S, Gençtoy G, Altun B, Kalyoncu U, Oto A, et al.:
Association of mineral metabolism with an increase in cellular adhesion
molecules: Another link to cardiovascular risk in maintenance
haemodialysis? Nephrology Dialysis Transplantation 21: 999-1005,
2006.
34. Papayianni A, Alexopoulos E, Giamalis P, Gionanlis L, Belechri AM,
Koukoudis P, et al.: Circulating levels of ICAM-1, VCAM-1, and MCP-1 are
increased in haemodialysis patients: Association with inflammation,
dyslipidaemia, and vascular events. Nephrol Dial Transplant 17:
435-441, 2002.